Full Text View
Tabular View
No Study Results Posted
Related Studies
Combination Chemotherapy With or Without Oblimersen in Treating Patients With Extensive-Stage Small Cell Lung Cancer
This study has been completed.
Study NCT00042978   Information provided by National Cancer Institute (NCI)
First Received: August 5, 2002   Last Updated: April 4, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lung Cancer
Additional conditions recognized in this trial
Carcinoma, Small Cell
Lung Neoplasms
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Carcinoma, Neuroendocrine
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
oblimersen sodium
carboplatin
etoposide
Additional drug interventions recognized in this trial
Etoposide phosphate
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Cancer and Leukemia Group B
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services